Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease characterized by the recurrence of transient wheals (hives), angioedema, or both for more than 6 weeks. 1 Several mechanisms have been investigated as possibly contributing to the pathogenesis of CSU, including infections, food intolerance, coagulation cascade, genetic factors, and autoimmunity. 1 Autoimmunity (ie, autoimmune mechanisms of skin mast cell activation) is held to be a frequent underlying cause of CSU. Two types of Gell and Coombs hypersensitivity reactions 2 have been postulated to be relevant in patients with autoimmune CSU.
A type I hypersensitivity to self, also called autoallergy, in which antigens crosslink the IgE on mast cells and basophils to cause release of vasoactive mediators (Fig 1) , was first suggested by Rorsman 3 in 1962 to explain urticaria-associated basopenia. A role of autoallergy in urticaria was also postulated from the finding in 1999 of IgE autoantibodies (AAbs) against the thyroid microsomal antigen in the serum of a female patient with CSU. 4 This work has been confirmed and extended to propose autoallergy in the pathogenesis of both CSU and chronic inducible urticaria. [5] [6] [7] [8] [9] [10] A Type II hypersensitivity reaction in which antibodies, usually IgG or IgM, bind to antigen on a target cell (Fig 1) was originally postulated after the identification of IgG-AAbs against IgE in 3 of 6 patients with CSU. 11 The presence of these AAbs was confirmed by Grattan et al 12 in 1991 in patients whose sera induced a wheal-and-flare response when injected intradermally: the autologous serum skin test (ASST). The presence of AAbs to the high-affinity receptor for IgE on mast cells and basophils (IgG-anti-FcεRI) in a subset of patients with CSU was reported by the same group 2 years later. 13 In theory, IgG-anti-FcεRII/CD23 AAbs that were identified in sera of patients with CSU can also elicit mast cell degranulation through activation of eosinophils, with the consequent release of major basic protein and other mast cell secretagogues (Fig 1) . 14 We assessed the evidence for a role of these 2 forms of autoimmunity in patients with CSU using Hill's 9 criteria of causality, which were developed by Sir Austin Bradford Hill, an English epidemiologist and statistician, as a research tool for the medical field (Table I) . 15, 16 These criteria should be viewed as guidelines rather than a checklist of definite causes. Furthermore, Hill did not indicate how many of the 9 criteria need to be fulfilled to define the relationship as causal. When we reviewed the data on autoimmunity and CSU, we categorized the strength of evidence for each criterion as ''insufficient,'' ''low,'' ''moderate,'' or ''high'' (Tables II and III) , as previously described. 17, 18 Finally, we assigned established levels of causality based on Hill's criteria (Table IV , see the ''Systematic review methodology'' in this article's Online Repository at www.jacionline.org). 19 
1: STRENGTH OF ASSOCIATION AND 2: CONSISTENCY Type I autoimmunity
The strength of association between IgE-AAbs and CSU is currently unknown, and the relative risks have not been assessed. Six independent studies from different teams evaluated the link between CSU and IgE-AAbs, such as IgE-anti-doublestranded DNA (dsDNA) 9 and IgE-anti-thyroperoxidase (TPO ;  Table V) . 5, 6, 10, 20, 21 Three of these studies show that serum levels of IgE-AAbs (anti-dsDNA or anti-TPO) are significantly higher in patients with CSU than in healthy subjects. 6, 9, 10 Three studies failed to reproduce an association between IgEAAbs and CSU. 5, 9, 20 In the first of these studies, all of 23 patients with CSU showed serum IgG-anti-TPO, but no patient had positive results for IgE-anti-TPO. 20 In the second study only 2 of 20 patients with CSU with IgG-anti-thyroid antibodies had detectable IgE-anti-thyroid antibodies. 5 In the third study Hatada et al 9 did not find differences in levels of IgE against thioredoxin, peroxiredoxin, or thyroglobulin between patients with CSU and healthy subjects. A radioimmunoassay or direct ELISA 5, 9, 20 approach was used in all 3 studies, where IgG-AAbs to the antigen can mask the presence of IgE-AAbs because competition. 22 In contrast, Altrichter et al, 6 who showed a high prevalence of IgE-anti-TPO in patients with CSU, used a site-directed human IgE capture ELISA in which IgE-anti-TPO does not compete with IgG-anti-TPO antibodies.
Strength of evidence: Low
Type II autoimmunity
Although the presence of IgG-AAbs to IgE and FcεRI has been repeatedly observed in patients with CSU (Table VI) , 11, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] the strength of association and relative risks have not been formally assessed. However, many independent studies have reported higher rates of IgG-anti-IgE, IgG-anti-FcεRI, or both in immunoassays in patients with CSU in comparison with healthy control subjects, [23] [24] [25] [26] atopic patients, 27, 28 patients with inducible urticaria, 24 and patients with psoriasis. 28 This was not the case in all studies. [29] [30] [31] [32] [33] The rates of IgG-anti-FcεRI positivity in patients with CSU were investigated by 14 studies, and the prevalence of these AAbs ranged from 4% to 64%. In healthy control subjects the prevalence of IgG-anti-FcεRI ranged from 0% to 57%, as reported by 10 studies (Table VI) . Rates of IgG-anti-IgE positivity in patients with CSU ranged from 0% to 69% (7 studies) compared with 0% to 30% in healthy control subjects (6 studies, Table VI ). In all studies IgG-AAbs were detected by means of Western blotting, ELISA, or both or immunoenzymetric assays.
Strength of evidence: Moderate
3: BIOLOGICAL PLAUSIBILITY AND 4: COHERENCE Type I autoimmunity
Several independent findings support the plausibility and coherence of type I autoimmunity as a relevant cause of CSU (Table VII) . 6, 9, 10, [41] [42] [43] [44] IgE-AAbs in the blood of patients with CSU, such as IgE-anti-TPO and IgE-anti-dsDNA, have been shown to bind to basophils and to induce degranulation after interaction with their specific antigen. 9, 10 A second reason why it is plausible that IgE-anti-self can induce the signs and symptoms of CSU is the analogy with acute urticaria caused by IgE-mediated immediate hypersensitivity. IgE against a wide range of environmental allergens is known to cause acute urticaria. 63 Also, IgE-AAbs in some patients with CSU might contribute to higher levels of total IgE, 10 which was proposed to be a potential marker for severe CSU. 64 One study reported significantly higher levels of total IgE in patients with urticaria with IgE-anti-TPO compared with those without AAbs. 10 Additional evidence-based arguments for the coherence of type I autoimmunity as a cause of CSU are that other autoimmune diseases are common comorbidities of patients with CSU 6, 41 and that wheals in patients with CSU show features of IgE/allergen-induced late-phase cutaneous reactions, including T-cell infiltrates (Table VII) . 42 able to release histamine from healthy donor mast cells 45 and basophils. 12 IgG-mediated basophil activation in vitro has also been demonstrated repeatedly with the serum of patients with CSU. 46 Moreover, these IgG-AAbs can activate complement and generate C5a, a potent inducer of human skin mast cell degranulation. 47, 48 AAs, Autoantigens; HCs, healthy control subjects; RA, rheumatoid arthritis.
Significant circumstantial evidence for the coherence of type II autoimmunity as a cause of CSU includes the fact that patients with positive IgG-AAbs and CSU often have other autoimmune comorbidities, such as autoimmune thyroiditis, 41, 49 can show Tlymphocytic infiltration of wheals, [42] [43] [44] exhibit decreased numbers of regulatory T cells, 50 appear to have an HLAassociated genetic predisposition for autoimmune diseases (class I and II alleles), 51 and exhibit cytokine profiles indicative of autoimmunity. 52 
Strength of evidence: High

5: TEMPORALITY Type I autoimmunity
The temporal relationship between IgE-AAbs and CSU development has not yet been investigated. However, the efficacy of anti-IgE (omalizumab) and the relapse of the disease after drug withdrawal can be seen as indirect evidence for temporality. 7, 66 Strength of evidence: Insufficient
Type II autoimmunity
Currently, there are no published data on the temporal relationship between IgG-AAbs and CSU development. Positive ASST results reportedly persist after CSU remission in some studies, 67, 68 whereas in other studies the ASST result became negative after remission of CSU in most patients. 69 , 70 Grattan et al 69 demonstrated that ASST results are positive in patients with CSU in remission when done with stored sera but not with fresh sera. These findings suggest that IgG-anti-FcεRI and IgG-anti-IgE antibodies might decrease during remission in some patients.
Strength of evidence: Insufficient
6: DOSE-RESPONSE RELATIONSHIP (BIOLOGICAL GRADIENT) Type I autoimmunity
There have been no studies that assessed the link between the incidence or severity of CSU and IgE-AAb levels.
Strength of evidence: Insufficient DM, Dermatomyositis; HCs, healthy control subjects; PV, pemphigus vulgaris.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 6 Type II autoimmunity
The link between the risk of CSU and IgG-AAb levels against FcεRI or IgE has not been studied. However, it has been shown that serum levels of histamine-releasing IgG-anti-FcεRI-AAbs, but not of non-histamine-releasing IgG-anti-FcεRI-AAbs, correlate with disease severity 24, 53 and that their removal by means of plasmapheresis might lead to CSU remission. 54 Histaminereleasing activity followed IgG concentrations and clinical activity of CSU before and after plasmapheresis. 54 Additional indirect evidence appears to support this. Disease activity in patients with CSU is correlated with blood basopenia, 71 which, in turn, is reportedly linked to serum basophil histamine-releasing activity 72 and high levels of IgG-anti-FcεRI and IgG-anti-IgE. 29 Strength of evidence: Low-moderate
7: EXPERIMENT Type I autoimmunity
Omalizumab, a humanized anti-IgE mAb, has been shown in a randomized placebo-controlled clinical trial to be effective in patients with CSU with high levels of IgE-anti-TPO. 7 This suggests that omalizumab might protect against urticarial symptoms by reducing levels of IgE-AAbs, such as IgE-anti-TPO (Fig 2) .
Provocation testing is another way to assess the effects of altered AAb/autoantigen levels. Successful passive transfer of serum from a patient with symptomatic dermographism, a form of chronic inducible urticaria, to a monkey was shown. 73 In 1942, Rajka 74 described the successful passive transfer of solar urticaria from a patient to a healthy subject after intradermal injection of the patient's serum with subsequent light exposure of injected skin. These data were later confirmed by Kojima et al. 75 These types of passive transfer approaches are based on the Prausnitz-K€ ustner test, a test for the presence of IgEassociated immediate hypersensitivity reactions. 76 However, serum transfer studies do not necessarily confirm the presence of IgE-AAbs. In some cases transfer of other histaminereleasing serum factors, such as IgG-AAbs or thrombin, can also take place.
Strength of evidence: Moderate 
Strength of evidence Description
High High confidence that the evidence reflects the true effect: further research is very unlikely to change our confidence in the estimate of effect.
Moderate
Moderate confidence that the evidence reflects the true effect: further research might change our confidence in the estimate of effect and might change the estimate. Low Low confidence that the evidence reflects the true effect: further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
Insufficient
Evidence either is unavailable or does not permit a conclusion.
Levels of causality Description
Level 1 Causal relationship; well-conducted studies with realistic exposures have been replicated, and chance, bias, and confounding can be ruled out with reasonable confidence.
Level 2
Causal relationship is likely, with similar evidence to that for a causal relationship, but important uncertainties remain. Level 3 Causal relationship is suggested by the evidence, but chance, bias, and confounding cannot be ruled out. Level 4 Causal relationship cannot be adequately inferred; the available studies lack the quantity, quality, consistency, or statistical power on which to base a decision. Level 5 Causal relationship is not likely; the evidence from several studies suggests that a causal relationship is unlikely. Patients with aspirin-intolerant chronic urticaria were included; it was not defined whether patients with inducible urticaria were excluded. àAnti-dsDNA IgE levels were significantly higher in patients with CSU than in healthy subjects, but no differences in levels of thioredoxin-, peroxiredoxin-, and thyroglobulinreactive IgE were seen. §One patient had anti-TPO IgE antibody, and 1 patient had anti-thyroglobulin IgE. kOne of the control subjects had autoimmune thyroiditis, and 2 others had allergic rhinitis. {Patients with known Hashimoto thyroiditis but with no history of urticaria.
Type II autoimmunity
Experimental evidence for a pathogenic role of IgG-AAbs comes from the demonstration that heterologous and autologous injections of IgG-anti-FcεRI-positive serum can induce whealand-flare reactions. Grattan and Francis 55 reported the development of wheals in vivo after intradermal injection of plasma from a patient with CSU into the skin of a healthy volunteer with previously negative ASST results. However, attempts to perform a cross-species passive transfer of sera from patients with CSU with positive ASST results to guinea pigs 77 or macaque monkeys 78 did not produce any success. The ASST is considered to be a screening test for autoimmune CSU because of IgG-anti-IgE AAbs, anti-FcεRI AAbs, or both. 79 Rates of ASST positivity were higher in patients with CSU compared with those in healthy control subjects, 26,80-82 atopic patients, 80, 83 and patients with inducible urticaria 80 in some studies but not others. 84, 85 A positive ASST result is significantly associated with CSU and female sex. 83 A negative ASST result has a high predictive value for the absence of circulating functional AAbs. Direct evidence of mast cell degranulation in wheals of positive ASST responses of a patient with CSU has been provided by using electron microscopy. 43 Autoimmune CSU in patients with positive ASST results requires in vitro demonstration of IgG-AAbs against FcεRI or IgE by means of ELISA or Western blotting and testing of these IgG-AAbs for functional activity, such as by use of a basophil -, No data; AC, atopic control subjects; AD, atopic dermatitis; AU, acute urticaria; ChU, cholinergic urticaria; CoU, cold urticaria; DM, dermatomyositis; DP, delayed-pressure urticaria; DU, dermographic urticaria; HCs, healthy control subjects; IEMA, immunoenzymetric assay; Ps, psoriasis; PV, pemphigus vulgaris; RA, rheumatoid arthritis; UP, urticaria pigmentosa; UV, urticarial vasculitis; WB, Western blot. *Data were not shown in the article. Ten atopic and 13 nonatopic control subjects. àLow levels of anti-FcεRI AAbs in all tested blood samples. §Patients with immunoreactive histamine-releasing anti-FcεRI AAbs (n 5 20, 26%) and immunoreactive anti-FcεRI AAbs without histamine-releasing activity (n 5 12, 15%). kSome normal sera were positive and were considered to have insignificant titers. {RA (27) , SLE (26) . #AC (8) J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 6 activation test (BAT). 79 IgG autoreactivity measured by using the BAT was observed more frequently in patients with CSU than in healthy control subjects in many studies. 13, 24, 26, 45, 72, 80 Approximately 25% of patients with CSU have both a positive ASST result and a positive BAT result. 79 Furthermore, ASST and BAT positivity in patients with CSU are associated with longer duration of the disease in some studies, 34, 86 although not in all 87 ; higher disease severity 53, 83, 88 ; and a poor response to antihistamine treatment. 34 The efficacy of omalizumab also supports a type II autoimmune pathomechanism in patients with CSU. 56 In patients with CSU with IgG-AAbs against IgE or FcεRI, the effect of omalizumab might be associated with the decrease in mast cell-bound IgE levels and the subsequent downregulation of FcεRI on mast cells and basophils (Fig 2) . 56, 66 Thus patients with CSU with type II autoimmunity can be expected to show a slow response to omalizumab treatment, although this has not yet been confirmed experimentally.
Finally, the effectiveness of immunosuppressive treatments, such as cyclosporine, 89 intravenous immunoglobulin, 57 rituximab, 58 methotrexate, 59 and mycophenolate mofetil, 60 and the removal of AAbs by means of plasmapheresis 54 provide experimental evidence for a role of IgG-AAbs in the pathogenesis of CSU. Treatment with cyclosporine reduces the level of histamine-releasing IgG-AAbs, decreases ASST response rates, 61 and leads to inhibition of dose-dependent histamine release from mast cells and basophils. 62, 90 Patients with CSU with positive BAT results respond better to cyclosporine treatment than those with negative BAT results. 61 Arguments that challenge the concept of type II autoimmunity include the reported ASST positivity in some patients with CSU during remission 67, 68 and the lack of a clear correlation between immunoassays and functional assays. 35, 79 Strength of evidence: High
8: SPECIFICITY Type I autoimmunity
It is still unknown whether IgE-AAbs, by themselves, can induce CSU. Patients with CSU who express IgE against one autoantigen are likely to exhibit IgE against other autoantigens.
6,9
Strength of evidence: Insufficient 
Type II autoimmunity
It is still not known whether IgG-AAbs alone are able to induce CSU. It is thought that an IgG-anti-FcεRI/IgE-mediated activation of mast cells and basophils might be dependent on or augmented by other factors, such as complement C5a, which can activate skin mast cells through its CD88/C5aR receptor (Fig  1) . 35, 47, 48 However, there is evidence that complement is not necessary for CSU serum-induced basophil activation. 12, 28 Functionality of these IgG-AAbs also depends on IgG 1,3 subclasses. 91 IgG-AAbs against the low-affinity IgE receptor (FcεRII) can activate eosinophils, and their release of major basic protein and other mast cell secretagogues might contribute to the induction of CSU signs and symptoms (Fig 1). 14 Strength of evidence: Insufficient 9: ANALOGY Type I autoimmunity IgE against environmental allergens is responsible for the activation of mast cells in patients with allergic diseases, including anaphylaxis. 63 IgE-AAbs (directed to skin antigens) and autoallergic mast cell activation have been observed and described in patients with other chronic inflammatory skin diseases, such as bullous pemphigoid (BP) 92, 93 and atopic dermatitis. 94 IgE-anti-BP180 has been described to occur in up to 90% of untreated patients with BP, and mast cell degranulation by BP180 has been suggested to be a key trigger for the development of BP skin lesions, which often first manifest as wheals. 93 Recently, increased levels of IgE-AAbs against nuclear antigens, dsDNA, or TPO were described in patients with other autoimmune diseases, such as systemic lupus erythematosus (SLE) 94, 95 and autoimmune thyroiditis. 96 Levels of autoreactive antinuclear IgE were found to be significantly higher in patients with SLE and rheumatoid arthritis than in healthy control subjects. 97 
Strength of evidence: Moderate
Type II autoimmunity
The causal association between IgG-AAbs and different autoimmune diseases, such as pemphigus vulgaris, dermatomyositis, SLE, and BP, is well established. 98 
Strength of evidence: High
OVERALL EVIDENCE AND CONCLUSION
Taken together, the evidence in support of Hill's criteria is suggestive of a causal relationship (level 3 causality) for type I autoimmunity in patients with CSU and a likely cause of CSU (level 2 causality) for type II autoimmunity. In both cases activation of dermal mast cells to release histamine appears critical to the development of symptoms. Type I and II autoimmunity are likely to be relevant in CSU subpopulations rather than the same patients (although some patients might exhibit IgE-AAbs and IgG-anti-IgE/FcεRI). Arguments in support of this theory include the identification of 2 distinct subgroups of patients with CSU, one IgE-anti-TPO low and the other IgE-anti-TPO high, 6 the absence of a correlation between IgE-AAbs and ASST response, 6,9 the correlation of IgG-AAbs with disease activity/severity 24, 53 and the absence of such correlation in the case of IgE-AAbs, 6, 9 and different speeds of onset of action of omalizumab. 7, 56, 66, 99, 100 More than half of all omalizumab-treated patients with CSU become symptom free within 1 week of their first injection. This would be consistent with type I autoimmunity, in which omalizumab rapidly binds free IgE-AAbs and omalizumab-IgE complexes bind autoallergens and thus reduce mast cell activation (Fig 2) . 66 The remainder of patients respond more slowly to omalizumab. This would be consistent with type II autoimmunity, in which the slow loss of membrane-bound IgE and subsequently FcεRI from skin mast cells 100 renders them less susceptible to activation by IgG-antiIgE and IgG-anti-FcεRI, respectively.
On the one hand, the existence of natural anti-FcεRIa AAbs found in healthy subjects, as confirmed by ASST and BAT results, might be explained by the concept of ''conditional autoimmunity.'' 79 It is suggested that these AAbs can cause CSU only under certain conditions and that they become pathogenic over time, depending on the state of occupancy of FcεRI by its natural IgE ligand. On the other hand, AAbs do not lead to clinical manifestations in patients with many rheumatologic and allergic diseases and might be nonfunctional. 98 Future studies should be aimed at closing the gaps of knowledge on the role and relevance of type I and I autoimmunity in patients with CSU (Tables II and III) . For type I autoimmune CSU, standardized diagnostic tests need to be developed, the associations of IgE-AAbs and the risk for CSU development and CSU severity need to be characterized, the temporal relationship of IgE-AAbs and CSU development needs to be determined, and IgE-AAbs transfer and depletion studies need to be performed. For type II autoimmune CSU, the use of tests for functional IgG-anti-IgE and IgG-anti-FcεRI needs to be harmonized to assess whether these IgG-AAbs are risk factors for CSU, the link between these AAbs and disease severity should be determined, and the temporal relationship between IgG-anti-IgE/ FcεRI expression and CSU development and remission must be clarified. Finally, patients with autoimmune type I and II CSU should be compared for clinical differences and therapeutic responses to facilitate optimal treatment of both subpopulations of patients with CSU. 
SYSTEMATIC REVIEW METHODOLOGY
To find relevant trials, we performed a Medline and Google Scholar search of the literature published before March 2016 with the key words ''chronic urticaria,'' ''idiopathic urticaria,'' ''autoimmune urticaria,'' ''chronic spontaneous urticaria,'' or ''autoreactive urticaria.'' Three thousand nine hundred two publications were found for ''chronic urticaria,'' 1145 for ''idiopathic urticaria,'' 770 for ''autoimmune urticaria,'' 401 for ''chronic spontaneous urticaria,'' and 30 for ''autoreactive urticaria.'' After checking for doubles, titles and/or abstracts of 3950 reports were screened, and the remaining relevant 92 publications were included in the review. Full texts were obtained, if available.
The identified literature was primarily evaluated by the first author and the last author. To be included in the review, studies had to meet the following inclusion criteria: (1) direct relevance to the specific issue (studies on IgE and/or IgG autoantibodies, studies that included comparison groups, and studies that describe mechanisms of skin mast cells and/or basophils activation caused by autoantibodies, for example) and (2) no serious methodological limitations in the study with respect to the quality of the information for the selected outcome, as determined by the assessors.
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was chosen for the evaluation of the quality of evidence for Hill's criteria. E1 The overall strength/quality of evidence for each criterion was categorized as ''insufficient'' (very low), ''low,'' ''moderate,'' or ''high.'' E2 Finally, we assigned established levels of causality based on Hill's criteria (Table IV) . E3 The quality and strength of evidence were assessed independently by all authors for each criterion and then discussed in detail between the assessors, taking into consideration bias and study limitations. A consensus regarding the strength of evidence and levels of causality was finally achieved during discussion.
